Sym004: Phase Ib started

Symphogen said Merck began a 2-part, open-label, international Phase Ib trial of IV Sym004 in combination with platinum-doublets in about 89 patients with stage IV NSCLC. The first part will evaluate escalating doses of 6-18 mg/kg Sym004 with cisplatin/gemcitabine, cisplatin/pemetrexed and carboplatin/paclitaxel, while the second part will further evaluate the dose and platinum-doublet selected from the first part. ...